603259 药明康德
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入32,856,71718.61%39,241,43140,340,80739,354,77822,902,385
减:营业总成本21,256,2686.46%27,342,26828,708,59129,800,81118,574,516
    其中:营业成本17,538,0996.68%22,964,51523,728,80024,677,21714,592,256
               财务费用190,652-407.65%(786,684)(338,119)(247,968)84,082
               资产减值损失(410,113)1,939.92%(1,236,258)(156,509)(175,951)(33,056)
公允价值变动收益(34,436)-115.82%186,958(37,809)770,079(93,387)
投资收益4,098,540-2,586.83%604,162233,849187,9491,356,269
    其中:对联营企业和合营企业的投资收益440,686121.51%245,065(67,560)(46,271)(117,290)
营业利润15,066,06290.93%11,580,17511,872,28610,652,2496,037,725
利润总额15,037,06891.45%11,539,81211,831,99110,618,4766,015,609
减:所得税费用2,830,875125.98%1,972,0722,131,7311,715,866879,662
净利润12,206,19384.90%9,567,7409,700,2608,902,6115,135,947
减:非控股权益130,68190.28%117,43193,51188,89838,792
股东净利润12,075,51384.84%9,450,3089,606,7498,813,7135,097,155

市场价值指针
每股收益 (元) *4.25088.89%3.2803.2703.0101.750
每股派息 (元) *0.700--0.9820.9900.8930.517
每股净资产 (元) *23.92326.26%20.30218.57015.73713.020
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容